Denosumab is a fully human monoclonal antibody that targets RANK Ligand and is being investigated for its potential to prevent and treat a broad range of bone disease conditions including osteoporosis, bone metastases and their consequences, cancer treatment-induced bone loss due to hormone ablative therapy, multiple myeloma and bone erosions in rheumatoid arthritis. Denosumab is the first late-stage investigational therapy that specifically inhibits RANK Ligand, an essential mediator of the cells that break down bone.
A clinical trial at the National Institutes of Health found that a medication, denosumab, significantly reduced abnormal bone turnover in adults with fibrous dysplasia, a rare disease marked by weak and misshapen bones.
The drug denosumab is currently used to treat osteoporosis and bone metastases. For more than a decade, its potential therapeutic benefit in the treatment of breast cancer has also been studied.
Experts provide the first framework for treating a common and life-threatening metabolic complication of cancer known as hypercalcemia of malignancy in the Endocrine Society's new Clinical Practice Guideline.
Bone tissue homeostasis is maintained by a balance between bone formation by osteoblasts and bone resorption by osteoclasts.
Prostate cancer is the most common type of cancer among men in the United States aside from skin cancer, according to the Centers for Disease Control and Prevention.
One in six men being treated for advanced prostate cancer experiences a reduced sense of smell and taste, a symptom that could cause increased anxiety among patients because it is also a side effect of COVID-19, according to Tulane researchers.
New research presented at ACR Convergence, the American College Rheumatology's annual meeting, reveals that romosozumab, an osteoporosis drug, produces substantial gains in bone mineral density in the hip and lumbar spine within one year, and that transitioning patients to a potent antiresorptive drug can lead to even more bone density gains.
Some of the principal treatments for osteoporosis, denosumab, zoledronate and calcium, could have a protective effect against COVID-19 in patients who take them, specifically a 30 to 40% reduction in the rate of infection, according to the results of a joint study by Hospital del Mar, the Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University and the Pere Virgili Health Park.
News-Medical talks to Professor David Thomas about his recent research identifying the mechanisms behind cancer cells developing resistance to drugs.
The Endocrine Society joined a coalition of leading bone health organizations to release guidance for healthcare professionals treating patients with osteoporosis in the era of COVID-19.
As World Osteoporosis Day approaches (20 October), it marks a year-long campaign dedicated to raising global awareness of this bone disease. A major unmet need in this space is the low rate of diagnosis and treatment.
The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture).
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society. The Society introduced the guideline during a news conference on Monday at ENDO 2019, its annual meeting in New Orleans, La.
About one in every 100 people in the world takes glucocorticoids long term to treat immune-mediated diseases. However, glucocorticoids, such as prednisone, have a side effect -- they induce the bone loss called osteoporosis, causing an estimated yearly bone fracture rate of 5 percent.
Women who took a drug holiday (temporary or permanent discontinuation of a medicine) from using bisphosphonates for more than two years have a significantly higher risk of a hip fracture compared to others who continued their treatment, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.
The American College of Rheumatology's updated clinical guideline for the prevention and treatment of glucocorticoid-induced osteoporosis is now available online.
When cancer metastases, bone unwittingly offers a friendly place for tumor cell growth--only to have its hospitality betrayed by pathologic fractures, spinal cord compression, the need for bone surgery or irradiation, and an increased risk of death.
Amgen and UCB today announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of treatment with EVENITY™* (romosozumab), an investigational agent for postmenopausal women with osteoporosis.
A new study provides reassuring information about the short-term and long-term safety of denosumab, a monoclonal antibody that is used to treat postmenopausal osteoporosis.
Osteoporosis is preventable and treatable, but only a small proportion of people at risk for fractures are evaluated and treated, according to new osteoporosis guidelines written by an expert panel headed by Loyola Medicine endocrinologist Pauline M. Camacho, MD, FACE.